Cargando…

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data

BACKGROUND: To examine the impact on glycemic control of achieving postprandial glucose (PPG) target with lixisenatide, a once-daily glucagon-like peptide-1 receptor agonist approved in the US, in patients with uncontrolled type 2 diabetes (T2D) on basal insulin, an agent that primarily targets fast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Jaime A., Stager, William, Paranjape, Sachin, Berria, Rachele, Leiter, Lawrence A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961286/ https://www.ncbi.nlm.nih.gov/pubmed/31956422 http://dx.doi.org/10.1186/s40842-019-0088-5

Ejemplares similares

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
por: Ahrén, Bo, et al.
Publicado: (2016)

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
por: Hanefeld, Markolf, et al.
Publicado: (2017)

Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index
por: Bonadonna, Riccardo C., et al.
Publicado: (2017)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
por: Becker, Reinhard H. A., et al.
Publicado: (2015)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
por: Dailey, George, et al.
Publicado: (2019)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
por: Horton, Edward S., et al.
Publicado: (2010)

Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis
por: Yao, Jun, et al.
Publicado: (2023)

Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial
por: Su, Qing, et al.
Publicado: (2018)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
por: Nauck, Michael A., et al.
Publicado: (2009)

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
por: Davidson, J. A., et al.
Publicado: (2019)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis
por: Shu, Hua, et al.
Publicado: (2016)

Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study
por: Ihana, Noriko, et al.
Publicado: (2014)

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
por: Seino, Hiroaki, et al.
Publicado: (2016)

Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the LIGHTNING Study
por: Bosnyak, Zsolt, et al.
Publicado: (2019)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence
por: Schwartz, Naama, et al.
Publicado: (2018)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
por: Frias, Juan, et al.
Publicado: (2018)

Nutritional strategies to attenuate postprandial glycemic response
por: Pasmans, Kenneth, et al.
Publicado: (2022)

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures
por: Pettus, Jeremy H., et al.
Publicado: (2019)

Achieving glycemic control with intensive insulin therapy in the ICU
por: Vakalos, A, et al.
Publicado: (2008)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
por: Davidson, Jaime A.
Publicado: (2013)

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
por: Iizuka, Katsumi, et al.
Publicado: (2021)

Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal‐L‐C randomized trial
por: Yang, Wenying, et al.
Publicado: (2017)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
por: Feng, Wenhuan, et al.
Publicado: (2021)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Correlation of antidepressant target dose optimization and achievement of glycemic control
por: Grisham-Takac, Catlin, et al.
Publicado: (2019)

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
por: Miya, Aika, et al.
Publicado: (2017)

A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control
por: Chen, Bo Zhi, et al.
Publicado: (2020)

Eating disinhibition and vagal tone moderate the postprandial response to glycemic load: a randomised controlled trial
por: Young, Hayley A., et al.
Publicado: (2016)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r95bb78ghlmp7fdk4rdg9d4hdd